Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.71 |
| ▸ | USP2 | O75604 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | OSBP | P22059 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.52 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918378 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL289077 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL15935529 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6302509 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL15935854 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL288394 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL3425844 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9454951 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL10389496 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL19837228 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193391-A1 | INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | claimed |
| EP-3310367-A1 | INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS | President and Fellows of Harvard College (US) | 2018-04-25 | — | — | EP | claimed |
| WO-2016209806-A1 | INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-12-29 | — | — | WO | claimed |
| US-20230296574-A1 | ANALYSIS METHOD AND ANALYSIS SYSTEM FOR BILE ACIDS, STEROLS, AND HORMONES | KAZUSA DNA RESEARCH INSTITUTE (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4209782-A1 | ANALYSIS METHOD AND ANALYSIS SYSTEM FOR BILE ACIDS, STEROLS, AND HORMONES | Aderans Company Limited (JP) | 2023-07-12 | — | — | EP | disclosed |
| EP-2953604-B1 | COSMETIC COMPOSITION | UNILEVER GLOBAL IP LTD (GB) | 2022-06-22 | — | — | EP | disclosed |
| EP-3997237-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-2934433-B1 | COSMETIC COMPOSITION | UNILEVER GLOBAL IP LTD (GB) | 2022-02-02 | — | — | EP | disclosed |
| US-20210388447-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-16 | — | — | US | disclosed |
| US-11072629-B2 | Reprogramming of cellular adhesion | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3818151-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-2654779-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | Ludwig Institute for Cancer Research, Ltd. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-07-21 | — | — | US | disclosed |
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2219587-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | The Regents of the University of California (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064696-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-0203968-B1 | METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES | SCHAFFNER, Carl P. (US) | 1992-04-08 | — | — | EP | disclosed |
| US-4639420-A | Method for the immunoanalysis of cholesterol epoxides | SCHAFFNER CARL P (US) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | SREBF1, SREBF2, SGMS1 | NPC1L1 20/4885USP2 2160/4885LMNA 500/4885 |
| US-20180193391-A1 | INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS | NFATC1, CD4, ICOS | NPC1L1 4382/4885USP2 1324/4885LMNA 2461/4885 |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | NPC1L1 11/4885USP2 1613/4885LMNA 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.